211 related articles for article (PubMed ID: 29720510)
1. Efficacy and safety profile of xanthines in COPD: a network meta-analysis.
Cazzola M; Calzetta L; Barnes PJ; Criner GJ; Martinez FJ; Papi A; Gabriella Matera M
Eur Respir Rev; 2018 Jun; 27(148):. PubMed ID: 29720510
[TBL] [Abstract][Full Text] [Related]
2. Impact of doxofylline in COPD: A pairwise meta-analysis.
Cazzola M; Calzetta L; Rogliani P; Page C; Matera MG
Pulm Pharmacol Ther; 2018 Aug; 51():1-9. PubMed ID: 29705620
[TBL] [Abstract][Full Text] [Related]
3. Doxofylline is not just another theophylline!
Matera MG; Page C; Cazzola M
Int J Chron Obstruct Pulmon Dis; 2017; 12():3487-3493. PubMed ID: 29255355
[TBL] [Abstract][Full Text] [Related]
4. Management of chronic obstructive pulmonary disease. Statement about theophyllines is misleading.
O'Driscoll BR
BMJ; 2003 Apr; 326(7393):821; author reply 821. PubMed ID: 12689985
[No Abstract] [Full Text] [Related]
5. The effect of doxofylline in asthma and COPD.
Cazzola M; Matera MG
Respir Med; 2020 Apr; 164():105904. PubMed ID: 32094104
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease.
Lal D; Manocha S; Ray A; Vijayan VK; Kumar R
J Basic Clin Physiol Pharmacol; 2015 Sep; 26(5):443-51. PubMed ID: 25894641
[TBL] [Abstract][Full Text] [Related]
7. Xanthines and Phosphodiesterase Inhibitors.
Spina D; Page CP
Handb Exp Pharmacol; 2017; 237():63-91. PubMed ID: 27844172
[TBL] [Abstract][Full Text] [Related]
8. A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study.
Calzetta L; Matera MG; Goldstein MF; Fairweather WR; Howard WW; Cazzola M; Rogliani P
Pulm Pharmacol Ther; 2020 Feb; 60():101883. PubMed ID: 31884206
[TBL] [Abstract][Full Text] [Related]
9. Prescription Status and Clinical Outcomes of Methylxanthines and Leukotriene Receptor Antagonists in Mild-to-Moderate Chronic Obstructive Pulmonary Disease.
Lee JK; Rhee CK; Kim K; Ra SW; Lee JH; Jung KS; Yoo KH; Kim YI; Kim DK
Int J Chron Obstruct Pulmon Dis; 2019; 14():2639-2647. PubMed ID: 31819397
[TBL] [Abstract][Full Text] [Related]
10. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
11. Doxofylline: a new generation xanthine bronchodilator devoid of major cardiovascular adverse effects.
Dini FL; Cogo R
Curr Med Res Opin; 2001; 16(4):258-68. PubMed ID: 11268710
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations.
Rogliani P; Matera MG; Ritondo BL; De Guido I; Puxeddu E; Cazzola M; Calzetta L
Pulm Pharmacol Ther; 2019 Dec; 59():101841. PubMed ID: 31520718
[TBL] [Abstract][Full Text] [Related]
13. Doxofylline: a "novofylline".
Page CP
Pulm Pharmacol Ther; 2010 Aug; 23(4):231-4. PubMed ID: 20380886
[TBL] [Abstract][Full Text] [Related]
14. Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies.
Martinez FJ; Rabe KF; Lipworth BJ; Arora S; Jenkins M; Martin UJ; Reisner C
Int J Chron Obstruct Pulmon Dis; 2020; 15():99-106. PubMed ID: 32021148
[TBL] [Abstract][Full Text] [Related]
15. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-analysis of randomised trials.
Barr RG; Rowe BH; Camargo CA
BMJ; 2003 Sep; 327(7416):643. PubMed ID: 14500434
[TBL] [Abstract][Full Text] [Related]
16. Comparative study on the efficacy of tiotropium bromide inhalation and oral doxofylline treatment of moderate to severe stable chronic obstructive pulmonary disease.
Wang T; Luo G; Hu Y; Li F; Ma J; Wang J; Zuo P; Xiong W; Liu X; Zhao J; Xiong S; Zhang Z; Li C; Zhao S; Sun J; Xu Y
J Huazhong Univ Sci Technolog Med Sci; 2011 Oct; 31(5):614. PubMed ID: 22038349
[TBL] [Abstract][Full Text] [Related]
17. Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study.
Kim CJ; Yoon HK; Park MJ; Yoo KH; Jung KS; Park JW; Lim SY; Shim JJ; Lee YC; Kim YS; Oh YM; Kim S; Yoo CG
Int J Chron Obstruct Pulmon Dis; 2017; 12():1589-1596. PubMed ID: 28615931
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies.
Ohar JA; Bowling A; Goodin T; Price B; Ozol-Godfrey A; Sharma S; Sanjar S
Int J Chron Obstruct Pulmon Dis; 2019; 14():461-470. PubMed ID: 30863047
[TBL] [Abstract][Full Text] [Related]
19. Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2).
Calzetta L; Hanania NA; Dini FL; Goldstein MF; Fairweather WR; Howard WW; Cazzola M
Pulm Pharmacol Ther; 2018 Dec; 53():20-26. PubMed ID: 30219705
[TBL] [Abstract][Full Text] [Related]
20. Treatment of moderate chronic obstructive pulmonary disease (stable) with doxofylline compared with slow release theophylline--a multicentre trial.
Santra CK
J Indian Med Assoc; 2008 Dec; 106(12):791-2, 794. PubMed ID: 19370950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
